Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting
Vanda Pharmaceuticals reported positive Phase III results from Study 3601 showing NEREUS (tradipitant) significantly reduced GLP-1 (semaglutide)-induced vomiting, meeting the primary endpoint with a 27% relative reduction (p=0.006). Higher-burden outcomes showed even larger effects: 60% relative reduction in frequent multi-day vomiting and 81% reduction in extreme vomiting versus placebo, with no new safety signals.
Key figures
- Drug Name
- NEREUS (tradipitant)
- Phase Of Trial
- Phase III
- Extreme vomiting
- 2.8% vs 14.6% placebo (p=0.0003), 81% relative reduction
- Glp1 market size
- $50 billion
- Frequent multiday vomiting
- 6.3% vs 15.9% placebo (p=0.008), 60% relative reduction
- Primary endpoint any vomiting
- 43.0% vs 58.5% placebo (p=0.006), 27% relative reduction
- Key secondary vomiting severe nausea
- 33.1% vs 50.6% placebo (p=0.002), 35% relative reduction
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.